Overview

Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Dementia (Alzheimer's Disease) is sometimes called "Type 3 Diabetes" because of the strong connection between Type 2 diabetes (a function of insulin resistance) with Dementia. The investigators therefore hypothesize that Reducing Insulin Resistance using Intensive Lifestyle Intervention (Exercise and Weight loss) + Metformin Treatment in Prediabetic & diet-control-only Diabetic overweight and mildly cognitively impaired individuals 55 years or older would lead to better Cognitive Function (compared to standard care) after 2 years. Subjects will be monitored and assessed using a battery of Cognitive and psychological tests and PET scans to demonstrate glucose utilization in the relevant areas of the brain. This 3-year open-label study aims to recruit 360 subjects with 50% (180 subjects) randomized to receiving Intensive lifestyle intervention with Metformin (if diabetic) vs the other 50% who would receive only the usual standard level of care in the primary care setting.
Phase:
Phase 4
Details
Lead Sponsor:
SingHealth Polyclinics
Collaborators:
Agency for Science, Technology and Research
Changi General Hospital
Duke-NUS Graduate Medical School
Khoo Teck Puat Hospital
National University Hospital, Singapore
National University, Singapore
Singapore Clinical Research Institute
Singapore General Hospital
Treatments:
Insulin
Metformin